伐尼克兰或尼古丁替代治疗初始失败后的戒烟:一项随机临床试验
在这项序贯多分配随机试验中,490名吸烟者先接受6周伐尼克兰或联合尼古丁替代治疗(CNRT)。未戒烟者再随机继续、换药或加量6周。伐尼克兰初始未戒烟者加量优于继续(绝对风险差18%),CNRT初始未戒烟者加量或换伐尼克兰优于继续(绝对风险差6%)。
要点
- 伐尼克兰初始未戒烟者,加量较继续治疗提高戒烟率,绝对风险差18%。
- CNRT初始未戒烟者,加量或换伐尼克兰均优于继续,绝对风险差6%。
- 6个月持续戒烟仅见加量组获益,换药组未显示优于继续。
核心结论
- 伐尼克兰初始未戒烟者加量优于继续;CNRT初始未戒烟者加量或换伐尼克兰优于继续,可能为可行补救策略。
研究设计与样本
- 双盲、安慰剂对照、序贯多分配随机试验,2015年6月至2019年10月在德克萨斯州一家烟草治疗门诊开展。
- 490名志愿者先随机接受6周伐尼克兰或CNRT,6周后未戒烟者再随机继续、换药或加量6周。
主要发现
- CNRT组191名初始未戒烟者中,继续组90人(47%)戒烟率8%(95%CrI 6%至10%),加量组50人(33%)14%(95%CrI 10%至18%),换伐尼克兰组51人(34%)14%(95%CrI 10%至18%),绝对风险差6%(95%CrI 6%至11%)。
- 伐尼克兰组157名初始未戒烟者中,加量组39人(32%)戒烟率20%(95%CrI 16%至26%),换CNRT组41人(34%)0(95%CrI 0至0),继续组77人(49%)3%(95%CrI 1%至4%),绝对风险差-3%(95%CrI -4%至-1%)。
- 伐尼克兰加量较继续的绝对风险差18%(95%CrI 13%至24%),后验概率超过99%。
- 6个月持续戒烟的次要结局表明,仅CNRT和伐尼克兰加量组较继续初始剂量有获益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Most people who smoke do not quit on their initial attempt. OBJECTIVE: To determine the best subsequent strategy for nonabstinence following initial treatment with varenicline or combined nicotine replacement therapy (CNRT). DESIGN, SETTING, AND PARTICIPANTS: Using a double-blind, placebo-controlled, sequential multiple assignment randomized trial, 490 volunteers were randomized to receive 6 weeks of varenicline or CNRT. After 6 weeks, nonabstainers were rerandomized to continue, switch, or increase medication dosage for 6 additional weeks. The study was conducted from June 2015 through October 2019 in a Texas tobacco treatment clinic. INTERVENTIONS: The initial treatment was 2 mg/d of varenicline or the combined replacement therapy of a 21-mg patch plus 2-mg lozenge. The rerandomized participants either continued with their initial therapies, switched between varenicline and CNRT, or increased dosages either to 3-mg or more of varenicline or to a 42-mg patch and lozenges. All received weekly brief counseling. MAIN OUTCOMES AND MEASURES: Biochemically verified 7-day point prevalence abstinence at the end of treatment at 12 weeks. RESULTS: The 490 randomized participants (210 female [43%], 287 non-Hispanic White [58%], mean age, 48.1 years) smoked an average of 20 cigarettes per day. After the first phase, 54 participants in the CNRT group were abstinent and continued their therapy; of the 191 who were not abstinent, 151 were rerandomized, and the 40 who did not return for rerandomization were assigned to continue their initial CNRT condition in phase 2. The end-of-treatment abstinence rate for the 191 phase 1 nonabstainers was 8% (95% credible interval [CrI], 6% to 10%) for the 90 (47%) who continued at the dosage condition, 14% (CrI, 10% to 18%) for the 50 (33%) who increased their dosage, and 14% (95% CrI, 10% to 18%) for the 51 (34%) who switched to varenicline (absolute risk difference [RD], 6%; 95% CrI, 6% to 11%) with more than 99% posterior probability that either strategy conferred benefit over continuing the initial dosage. After the first phase, 88 participants in the varenicline group were abstinent and continued their therapy; of the 157 who were not abstinent, 122 were rerandomized and 35 who did not return for rerandomization were assigned to continue with the varenicline condition. The end-of-treatment abstinence rate for the 157 phase 1 nonabstainers was 20% (95% CrI, 16% to 26%) for the 39 (32%) who increased their varenicline dosage, 0 (95% CrI, 0 to 0) for the 41 (34%) who switched CNRT, and 3% (95% CrI, 1% to 4%) for the 77 (49%) who were assigned to the continued varenicline condition (absolute RD, -3%; 95% CrI, -4% to -1%) with more than 99% posterior probability that continuing varenicline at the initial dosage was worse than switching to a higher dosage. Furthermore, increasing the varenicline dosage had an absolute RD of 18% (95% CrI, 13% to 24%) and a more than 99% posterior probability of conferring benefit. The secondary outcome of continuous abstinence at 6 months indicated that only increased dosages of the CNRT and varenicline provided benefit over continuation of the initial treatment dosages. CONCLUSIONS AND RELEVANCE: For individuals who smoked but did not achieve abstinence after treatment with varenicline, increasing the dosage enhanced abstinence vs continuing, whereas for nonabstainers initially treated with CNRT, a dosage increase or switch to varenicline enhanced abstinence and may be viable rescue strategies. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02271919.
引用
- Cinciripini PM, Green CE, Shete S, et al. Smoking Cessation After Initial Treatment Failure With Varenicline or Nicotine Replacement: A Randomized Clinical Trial. JAMA. 2024. PMID: 38696203. doi:10.1001/jama.2024.4183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。